The New England Journal of Medicine retracted a pivotal phase 3 article for Amgen’s Tavneos (avacopan) after academic authors reported that primary endpoint assessments in nine patients were re-adjudicated after database lock and unblinding. The retraction compounds Amgen’s regulatory and litigation pressures tied to FDA scrutiny of study conduct.